We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Globus Medical Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Globus Medical's musculoskeletal revenues rose 7.5% in Q2 2026, with base business sales up 10.9%.
GMED's U.S. Spine grew 7.3%, while Trauma climbed 31% year over year as PRECICE supply normalized.
Globus Medical ended Q2 with $507.7M in cash and no debt, supporting R&D and expansion investments.
Globus Medical, Inc. (GMED - Free Report) is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments. Also, product innovation and solid financial health add to the stock’s appeal. Unfavorable foreign exchange remains a concern for GMED’s operations.
Over the past year, this Zacks Rank #2 (Buy) stock has risen 26.5% compared with the industry's 5.9% growth. The S&P 500 composite has risen 16.2% in the same time frame.
The renowned medical device company has a market capitalization of $12.55 billion. Globus Medical has an earnings yield of 6.5% against the industry’s negative 1.9% yield. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.9%.
Let’s delve deeper.
Upsides for GMED Stock
Musculoskeletal Share Gains Continue: Globus Medical continues to gain share in Musculoskeletal Solutions through broad-based growth across Spine and Trauma. In the second quarter of 2026, Musculoskeletal revenues rose 7.5% year over year despite a 14.3% decline in Nevro, while base business musculoskeletal sales increased 10.9%.
U.S. Spine grew 7.3%, marking a fifth straight quarter of above-market growth, and competitive hires doubled sequentially. International Spine advanced 13.8% as reported and 12.2% at constant currency, with double-digit gains across the EMEA, Latin America and APAC. Trauma rose 31% year over year and 18% sequentially as PRECICE supply normalized and the core portfolio gained share. Commercial reach and portfolio breadth should support share gains as tougher comparisons moderate reported U.S. Spine growth.
Steady Pace of Product Development: Globus Medical continues to use internal R&D and product cadence to deepen account relationships across spine, trauma and enabling technologies. In the second quarter of 2026, management said more than 60 development projects were underway, following more than 25 product launches during the prior 36 months.
During the quarter, the company launched AUTOBAHN Hip Fastener, TENSOR Suture Button System and RELINE ONE, while patient-specific SCRIPT spacers and rods are expected later in the third quarter. These products expand the portfolio and increasingly connect implants with planning software and the Excelsius ecosystem.
Financial Flexibility: Globus Medical ended the second quarter of 2026 with $507.7 million of cash and cash equivalents and $87.4 million of short-term marketable securities. The company remains debt-free, providing financial flexibility to fund R&D, sales-force investments and manufacturing expansion from internal resources. Operating cash flow reached $412.1 million in the first half of 2026. The company repurchased $136.1 million of stock during the second quarter, with $253.9 million remaining under its authorization.
Image Source: Zacks Investment Research
What Ails GMED?
Currency Exposure Persists: Globus Medical remains exposed to foreign-exchange volatility through its international operations. The company recorded an $860,000 foreign currency transaction loss in the second quarter of 2026 and a $3.0 million loss in the first half. As international operations expand, adverse currency movements could create greater variability in reported earnings and reduce operating leverage.
Estimate Trend
The Zacks Consensus Estimate for GMED’s 2026 earnings per share (EPS) has remained unchanged at $4.74 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $3.20 billion, indicating an 8.7% rise from the year-ago reported number.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
OPKO Health, flaunting a Zacks Rank #1 at present, has an estimated 2026 earnings growth rate of 23.3% compared with the industry’s 16.6% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 95.1%. OPK shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Add Globus Medical Stock to Your Portfolio Now
Key Takeaways
Globus Medical, Inc. (GMED - Free Report) is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments. Also, product innovation and solid financial health add to the stock’s appeal. Unfavorable foreign exchange remains a concern for GMED’s operations.
Over the past year, this Zacks Rank #2 (Buy) stock has risen 26.5% compared with the industry's 5.9% growth. The S&P 500 composite has risen 16.2% in the same time frame.
The renowned medical device company has a market capitalization of $12.55 billion. Globus Medical has an earnings yield of 6.5% against the industry’s negative 1.9% yield. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.9%.
Let’s delve deeper.
Upsides for GMED Stock
Musculoskeletal Share Gains Continue: Globus Medical continues to gain share in Musculoskeletal Solutions through broad-based growth across Spine and Trauma. In the second quarter of 2026, Musculoskeletal revenues rose 7.5% year over year despite a 14.3% decline in Nevro, while base business musculoskeletal sales increased 10.9%.
U.S. Spine grew 7.3%, marking a fifth straight quarter of above-market growth, and competitive hires doubled sequentially. International Spine advanced 13.8% as reported and 12.2% at constant currency, with double-digit gains across the EMEA, Latin America and APAC. Trauma rose 31% year over year and 18% sequentially as PRECICE supply normalized and the core portfolio gained share. Commercial reach and portfolio breadth should support share gains as tougher comparisons moderate reported U.S. Spine growth.
Steady Pace of Product Development: Globus Medical continues to use internal R&D and product cadence to deepen account relationships across spine, trauma and enabling technologies. In the second quarter of 2026, management said more than 60 development projects were underway, following more than 25 product launches during the prior 36 months.
During the quarter, the company launched AUTOBAHN Hip Fastener, TENSOR Suture Button System and RELINE ONE, while patient-specific SCRIPT spacers and rods are expected later in the third quarter. These products expand the portfolio and increasingly connect implants with planning software and the Excelsius ecosystem.
Financial Flexibility: Globus Medical ended the second quarter of 2026 with $507.7 million of cash and cash equivalents and $87.4 million of short-term marketable securities. The company remains debt-free, providing financial flexibility to fund R&D, sales-force investments and manufacturing expansion from internal resources. Operating cash flow reached $412.1 million in the first half of 2026. The company repurchased $136.1 million of stock during the second quarter, with $253.9 million remaining under its authorization.
Image Source: Zacks Investment Research
What Ails GMED?
Currency Exposure Persists: Globus Medical remains exposed to foreign-exchange volatility through its international operations. The company recorded an $860,000 foreign currency transaction loss in the second quarter of 2026 and a $3.0 million loss in the first half. As international operations expand, adverse currency movements could create greater variability in reported earnings and reduce operating leverage.
Estimate Trend
The Zacks Consensus Estimate for GMED’s 2026 earnings per share (EPS) has remained unchanged at $4.74 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $3.20 billion, indicating an 8.7% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , OPKO Health (OPK - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPKO Health, flaunting a Zacks Rank #1 at present, has an estimated 2026 earnings growth rate of 23.3% compared with the industry’s 16.6% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 95.1%. OPK shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.